Infections and Biologic Therapy in Rheumatoid Arthritis

Slides:

Advertisements

Similar presentations

Stage B, a Pre-cursor of Heart Failure Jay N. Cohn, MD, Gary S. Francis, MD Heart Failure Clinics Volume 8, Issue 1, Pages xvii-xviii (January 2012) DOI:

Advertisements

Vitamin D in chronic kidney disease Adriana Dusso, Ph.D, Esther A. González, MD, FACP, Kevin J. Martin, MB, B.Ch, FASN Best Practice & Research Clinical.

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs Daniel H. Solomon, MD, MPH,

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs Daniel H. Solomon, MD, MPH,

Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums Geraldine Navarro, MD, Sara Taroumian, MD, Nashla Barroso,

My Treatment Approach to Rheumatoid Arthritis

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

New Views into the Prostate Cancer Genome

Pay for Performance in Neonatal-Perinatal Medicine—Will the Quality of Health Care Improve in the Neonatal Intensive Care Unit? A Business Model for Improving.

Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study S.-Y. Li, T.-J. Chen, K.-W. Chung,

Vibeke Strand, MD, MACR, Jasvinder A. Singh, MD, MPH

Building better therapy for children with acute lymphoblastic leukemia

My Treatment Approach to Rheumatoid Arthritis

Obsessive Compulsive Disorder: A Clinical Update

Leslie R. Harrold, MD, MPH, Daniel Peterson, MS, Ashley J

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Screening for colorectal, breast, and cervical cancer in the elderly: A review of the evidence Louise C. Walter, MD, Carmen L. Lewis, MD, MPH, Mary B.

Paraneoplastic and Cancer Treatment-Related Rheumatic Disorders

Volume 4, Issue 8, Pages (September 2018)

All-cause Mortality Associated with TNF-α Inhibitors in Rheumatoid Arthritis: A Meta- Analysis of Randomized Controlled Trials Lucile Poiroux, MD, Yannick.

Recognition for Conservative Care in Kidney Failure

Genomics in Rheumatic Diseases: Hope for the Future

Pediatric Intensive Care Treatment of Uncontrolled Status Epilepticus

Vector control: a cornerstone in the malaria elimination campaign

Treatment of hepatitis C

Volume 10, Issue 4, Pages ix-x (October 2014)

Hepatitis C Virus Infection in the Older Patient

Your Kidneys May Outlive You

Dangerous Fever in the Emergency Department

Preclinical Rheumatic Disease

Early Arthritis Rheumatic Disease Clinics

Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Clinical Trials to “Real-World” Heart Failure: Applying Risk Stratification to Deliver Personalized Care Ragavendra R. Baliga, MD, MBA Heart Failure.

Levofloxacin in the treatment of ventilator-associated pneumonia

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Preface Emergency Medicine Clinics

Carol Chenoweth, MD, Sanjay Saint, MD, MPH Critical Care Clinics

David H. Bruining, William J. Sandborn

Advances in ICD Therapy

A review of the current guidelines for allergic rhinitis and asthma

The Patient Experience: Patient-Reported Outcomes in Rheumatology

The role of antimalarial treatment in the elimination of malaria

Nat. Rev. Cardiol. doi: /nrcardio

American Journal of Kidney Diseases

Women with Rheumatoid Arthritis: The Unspoken Risk Factor

Clinical Microbiology and Infection

Demystifying Lung Disease in the Rheumatic Diseases

Atrial Fibrillation and Heart Failure: It Takes Two to Tango

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Lynda Anne Szczech, Ira L. Lazar Kidney International

Risk for Incident Renal Dialysis in a Managed Care Population

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Behram A. Khan, MD, Conrad Deel, MD, Richard N. Hellman, MD

A Three-Headed Approach to Kidney Involvement in Rheumatic Diseases

Improving management of neonatal infections

August Heidland, MD, Udo Bahner, MD, Spiros Vamvakas, MD

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Anil K. Saxena, MD, B.R. Panhotra, MD, PhD, MNAMS

Supportive care for patients with renal disease: Time for action

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Neurologic Manifestations of Rheumatic Diseases

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Acute and Chronic Seizures in Patients Older Than 60 Years

Patient Self-Management and Tracking

Infection and Malignancy in Rheumatic Diseases

Presentation transcript:

Infections and Biologic Therapy in Rheumatoid Arthritis Kevin L. Winthrop, MD, MPH Rheumatic Disease Clinics Volume 38, Issue 4, Pages 727-745 (November 2012) DOI: 10.1016/j.rdc.2012.08.019 Copyright © 2012 Elsevier Inc. Terms and Conditions

Fig. 1 Estimated incidences of serious infections in 100 patients per year by treatment and risk profile. Additional risk factors are 1 or 2 of the following: age greater than 60 years, chronic lung disease, chronic renal disease, or high number of treatment failures; 3 risk factors: 2 of these risk factors plus previous serious infections. TNFi, tumor necrosis factor inhibitor. (From Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914–20.) Rheumatic Disease Clinics 2012 38, 727-745DOI: (10.1016/j.rdc.2012.08.019) Copyright © 2012 Elsevier Inc. Terms and Conditions